Member Info for TommyD_19

Only August but no specific date is expected but not guaranteed

Always look out for the “long term investors” it seems it’s obligatory to mention it

I too like the play join the dots.

So many interesting patterns

The interesting paradox is that we know there are financial time constraints on the company and yet here they are hiring a senior medical writer.

We’re obviously not seeing the entire picture which is understandable given most of these events happen behind closed door and can only be announced in accordance with the regulatory rules. The company no doubt finds itself in a position that’s not ideal having added staff for a launch that didn’t happen and they may well be constrained within contractual obligations. Is that the boards fault in some way, well if we had a crystal ball we’d all be geniuses. It appears to be the board are making best use of the team they have given the circumstances and constraints they find themselves in. RM says they’re busy making the most of the team who no doubt bring reassurance and contacts within the market place, which is crucial right now in conversations which will change the current predicament. We can but wait to see from the coming announcement whether that’s comes to fruition. The impression I have from the AGM is the board are both competent and doing everything they can to promote the positives that came from Sprinter.

I’ll reserve judgement until the Winter but our current finances give us a breathing space for the board to show we had reason to trust them.

Investors beware:

There’s been a theme for a while on this board sometimes subtle and sometimes blatantly not.

Remember the only thing that counts are real facts which are far and few.

We know the company has finances to reach at least next summer
We know trials are taking place in the US and soon to be announced in the U.K.
We cannot know we will be on those trials until they’re announced for obvious reasons and some will play on that uncertainty. But ask yourself how the drug you’ve invested in fits into the landscape of the trials coming on to the scene this winter and whether we are a good fit.
We know the market has a huge gap for a broad spectrum drug and we know that thousand are dying in hospital due to Covid-19, not to mention the millions hospitalised each year through viral infections.
There’s a lot of uncertainty but we have some good news on data due soon.

Finally as Richard said at the AGM. He strongly envisages us treating patients this winter, this is key to improving the companies position.

In the gap between real news and conjecture, be patient and remember no one knows until it’s announced by the company.

But of course it would be a “worry” if they were losing staff. Wouldn’t it Mr C?

Thanks for the update and taking time to contact Synairgen

Stacey Adam said in her slide presentation

Expected first patient in, in August.

That was the last I heard, it’s unclear whether “In” means enrolled, dosed etc

Not sure where that date has been picked from. I’ve not seen any mention of first doing a patient on Strive on the 22nd Aug

If someone has the magic news link please feel free to post it below

There’s certainly some very good research out there on LC and interferons. If Synairgen have something important to say then you’d want someone presenting that along with other research that’s out there in a convincing way.
LC has a huge focus so any results Synairgen have need professional science based presentation.

It’s certainly a strange add at this moment given the company said they don’t envisage a product to market for a year and with no trials to report on. So you have to ask what is it a senior medical writer is going to be doing?

I don’t buy this “nothing to see hear” the timing is definitely something to see here.

There’s a thread being presented that we have no trials, they’ll take a year.
Nothing great expected from Activ2 or
Long Covid. Well if that’s true it would have been much cheaper to outsource the work if they’ve got nothing significant to say for a year?

I’m sure someone will post it soon.
As I didn’t find it it seems unfair for me to post the info

Dig a little on influenza and NIHR and it’s there

Can’t see they hire in-house now for a role not needed until trials end a year or more from now.
You could freelance the work until then adding to the companies overheads at a time when budgets are a concern with a full time role and at a senior level to twiddle their thumbs for a year doesn’t seem at all plausible to me.

Permanent can only be a positive for the business. Having someone in-house at a senior level writing key documents as listed in the spec suggest a company with a lot to say in the near future.

Otherwise they could just contract out the service when required which is probably what they’ve been doing as no one so far has found a previous role

Probably contracted out and now in-house.

But we have no evidence to suggest anyone left

And Yet here you are day in and out Mr C

Any sensible investor of the opinion things were only going one way would get out quickly.

You’re a terrible deramper

Mr. C has been calling for wholesale job reductions for months so I’m not clear how that’s now a worry

Surely it would be a positive for MR C.

At the AGM Richard said they needed all their hires as they were extremely busy.

It will be interesting to see Mr C back up his remarks and explain the contradiction in his statements

*NIHR not NIHRC

.

Sorry wrong thread

With exciting news coming out of NIHRC

Here’s two interesting articles on influenza

https://www.biorxiv.org/content/10.1101/2022.07.29.501947v1
Enhanced viral infectivity and reduced interferon production are associated with high pathogenicity for influenza viruses…This study improves our understanding of the role of interferon on distinguishing immunodynamics

https://journals.asm.org/doi/full/10.1128/jvi.00765-22?af=
Type I IFN response induced by IAV infection may remain at a low level after viral clearance or an increase in resident immune cells in the airways—either of which would contribute to reduction of SARS-CoV-2 replication”